Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Forget Teladoc and Buy This Healthcare Stock Instead
Telemedicine leader Teladoc Health (NYSE: TDOC) has been struggling for several years. The company’s services are no longer experiencing…
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…
U.S. Negotiates Lower Prices for Ozempic and 14 Other Drugs
The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening…
2 Giant Healthcare Stocks to Buy Hand Over Fist in November
Medical device maker Medtronic boasts an attractive yield and a long history of dividend growth. Pfizer is demonstrating…
How Recent Moves Are Rewriting the Story for Pfizer
Pfizer’s fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate…
Pfizer signals brewing digital health work
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
2 Strong Healthcare Stock Picks for Value Investors
These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era,…
Why Weight-Loss Drug Prices Are Falling| Business News
President Trump claimed credit Thursday for cutting prices on popular weight-loss drugs by Eli Lilly and Novo Nordisk.…
3 Healthcare Stocks Paying the Highest Dividends of 2025
Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little…
What will TrumpRx mean for patients? Who saves — and how much
Could “TrumpRx” be the prescription for lower drug prices? President Trump announced a landmark deal with Pfizer to…